NEW YORK, Nov. 19 (GenomeWeb News) - The Australian Proteome Analysis Facility will partner with LumiCyte to develop LCI's STS biochip platform technology and to accelerate proteomic biomarker discovery, the facility said today.
Under terms of the agreement, LCI will provide access to its STS biochip platform to support APAF's biomarker discovery-research efforts. Using mass-spectrometry techniques, APAF will provide a range of evaluation, validation and showcasing proteomic studies to characterize the performance of the STS platform.
APAF and LCI will apply collaboratively to the Australian government for funding to support the STS platform research.
Financial terms of the collaboration were not disclosed.